Atopic dermatitis (AD) is a common chronic inflammatory disease with a variable course, particularly prevalent in the pediatric population. Targeted therapies-such as monoclonal antibodies (mAbs) and Janus kinase (JAK) inhibitors-represent emerging treatment options. Dupilumab was the first mAb approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe AD. To describe a case series of patients under 12 years of age with moderate-to-severe AD treated with dupilumab, and to provide practical considerations for its clinical use. A multicenter, retrospective, descriptive observational study was conducted, including pediatric patients with moderate-to-severe AD treated with dupilumab. Demographic, clinical, and treatment response variables were collected. Ten patients with moderate-to-severe AD (mean baseline EASI score of 24.4 SD 12) and a history of prior treatment failure were included. A mean reduction of 13.5 points in EASI score range: 5.9-25.8 was observed after 6 months of treatment, along with a sustained decrease in individual scores over time. Follow-up duration ranged from 12 to 24 months. Reported adverse effects were mild and did not lead to treatment discontinuation. The findings of this study are consistent with existing literature supporting the efficacy and safety of dupilumab in children under 12 years of age with moderate-to-severe AD. Furthermore, the study provides practical guidance for its use in real-world clinical settings.
Escobar et al. (2025) studied this question.